2021
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors
Blank CU, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Sznol M. Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology 2021, 28: 5466-5479. PMID: 34940094, PMCID: PMC8700717, DOI: 10.3390/curroncol28060455.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaObjective response ratePEG-interferon α-2aPhase Ib studyInterferon α-2bArm BSolid tumorsCell carcinomaClinical activityΑ-2aΑ-2bIb studyVascular endothelial growth factor inhibitorsFrequent treatment-related toxicitiesHigher objective response rateMetastatic renal cell carcinomaArm DTreatment-related toxicityPreliminary clinical activityGrowth factor inhibitorsMetastatic solid tumorsAcceptable tolerabilityFactor inhibitorsSafety profileCombination therapy
2005
Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12
Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE. Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12. Journal Of Clinical Oncology 2005, 23: 8835-8844. PMID: 16314644, DOI: 10.1200/jco.2005.02.1691.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDose-Response Relationship, DrugHumansInterferon alpha-2Interferon-alphaInterferon-gammaInterleukin-12Leukocytes, MononuclearMiddle AgedNeoplasmsRecombinant ProteinsSignal TransductionSTAT1 Transcription FactorTime FactorsTreatment OutcomeConceptsPatients' peripheral blood mononuclear cellsPatient PBMCsInterferon alfa-2bIFN-gammaInterleukin-12Alfa-2bRhIL-12Advanced cancerIL-12Greater IFN-gamma productionPeripheral blood mononuclear cellsPeak levelsIL-12 administrationPlasma IFN-gammaIL-12 therapyDose-limiting toxicityIFN-gamma productionHuman interleukin-12Interferon Signaling PathwayAssessable patientsIntracellular STAT1Stable diseasePeripheral bloodMononuclear cellsLevels of STAT1